India's Arch on the block; seeks strategic investor
This article was originally published in Scrip
Executive Summary
The Indian intermediates and active pharmaceutical ingredients (API) manufacturing firm, Arch Pharmalabs, is on the block – apparently coming full circle from the heady days when it drew significant private equity interest to when it saw key investor Japan's Mitsui & Co quietly exit, apparently for a song.